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To develop a herpes virus vaccine that can induce immunity for an extended period, a recombinant Marek’s disease (MD)
virus (MDV) CVI-988 strain expressing infectious bursal disease virus (IBDV) host-protective antigen VP2 at the US2 site
(rMDV) was developed under the control of an SV40 early promoter. Chickens vaccinated with the rMDV showed no clinical
signs and no mortality and 55% of the chickens were considered protected histopathologically after challenge with very
virulent IBDV (vvIBDV), whereas all of the chickens vaccinated with the conventional IBDV vaccine showed no clinical signs
and were protected. Chickens vaccinated with the CVI-988 or chickens in the challenge control showed severe clinical signs
and high mortality (70–75%) and none of them were protected. Also, the rMDV conferred full protection to chickens against
vvMDV just as the CVI-988 strain did, whereas 90% of the challenge control chickens died of MD. Antibody levels against
IBDV and MDV following the vaccination increased continuously for at least 10 weeks. No histopathological lesions in the
rMDV-vaccinated chickens and no contact transmission of the rMDV to their penmates were confirmed. These results
demonstrate that an effective and safe recombinant herpesvirus-based IBD vaccine could be constructed by expressing the
VP2 antigen at the US2 site of the CVI-988 vaccine strain. © 1999 Academic Press
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eINTRODUCTION
Infectious bursal disease (IBD) causes considerable
conomic losses in the poultry industry by inducing se-
ere clinical signs, immunosuppression, and high mor-
ality ($50%) in chickens (Lukert and Saif, 1997). The
ursa of Fabricius (BF) is a target organ for the IBD virus
IBDV) (Ka¨ufer and Weiss, 1980). B lymphocytes are de-
troyed by IBDV infection (Tanimura et al., 1995; Tsuka-
oto et al., 1995), followed by severe immunosuppres-
ion in chickens (Lukert and Saif, 1997). IBDV is a mem-
er of the Birnaviridae family, whose genome consists of
wo segments of double-stranded RNA (dsRNA) (Kibenge
t al., 1988): segment B encodes the putative dsRNA
olymerase VP1 (Spies and Mu¨ller, 1990; Spies et al.,
987), and segment A encodes two proteins, small and
arge. A small protein, VP5, is present in infected cells
ut is not essential for viral replication in cell culture
Mundt et al., 1997). A large protein is processed to three
ature viral proteins (VP2, VP3, and VP4). Both VP2 and
P3 are major structural proteins of IBDV particles (Bot-
cher et al., 1997), and VP4 may be a protease (Kibenge
t al., 1988). VP2 is the conformational host-protective
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352ntigen of IBDV (Becht et al., 1988; Fahey et al., 1989,
991b) and also an apoptotic inducer (Fernandez-Arias et
l., 1997). VP3 is the group-specific antigen but the pro-
ection roles need to be determined (O¨ppling et al.,
991a; Reddy et al., 1992).
Although IBD can be protected by several live IBDV
accines, it is often difficult to protect field chickens with
he use of live vaccines because the vaccines are sus-
eptible to maternal antibodies (Lukert and Saif, 1997;
sukamoto et al., 1995b). In addition, some live vaccines
ause moderate bursal atrophy (Mazariegos et al., 1990),
hich may allow opportunistic bacterial infections (Luk-
rt and Saif, 1997). Some characteristics of live IBDV
accines such as antigenicity and virulence are not sta-
le (Muskett et al., 1985). Hence, the development of
afer and more efficacious vaccines against IBDV is
equired in the field.
Marek’s disease (MD) is a transmissible malignant
-cell lymphoma of chickens and is the most common
ymphoproliferative disease in chickens. MD is caused
y serotype 1 MD viruses (MDV) (Calnek and Witter,
997). Although MDV has been classified as a gamma-
erpesvirus on the basis of its biological properties, the
ene structural data suggest that it should be classified
s an alpha-herpesvirus. MD has been controlled in the
oultry industry for more than 25 years by serotype 1, 2,
nd 3 live MDV vaccines (Calnek and Witter, 1997). The
ield experience has clearly demonstrated the safety and
ffectiveness of the MDV vaccines as a viral vector.The MDV vaccines have some ideal characteristic as
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353PROTECTION AGAINST IBDV AND MDV WITH RECOMBINANT MDVrecombinant vaccine vector. (i) The MDV as a herpes-
irus infects chickens persistently, and so the vaccine
mmunity may also continue to the end of the chickens’
ives. (ii) In practice, only MDV vaccines can be inocu-
ated into day-old field chicks that have high titers of
aternal antibodies because the degree of growth inter-
erence of MDV in vivo by the maternal antibodies is less
han that of some other virus vaccines. The MDV vac-
ines are virus-infected cell vaccines and spread by a
ell-to-cell transmission mechanism in chickens. In con-
rast, other virus vaccines are susceptible to maternal
ntibodies. (iii) The MDV genome is large enough for
ultiple foreign genes to be inserted in its genome. Five
oreign gene-insertion sites in the unique short (US)
egion of serotype 1 MDV (Cantello et al., 1991; Parcells
t al., 1994; Sakaguchi et al., 1993, 1994; Sonoda et al.,
996) and the two gene-insertion sites in the US region of
erotype 3 MDV, herpesvirus of turkey (HVT) (Darteil et
l., 1995; Morgan et al., 1992), were identified. A recom-
inant HVT (rHVT) expressing IBDV VP2 at the gI site
as constructed but in vivo replication of the rHVT was
ot efficient; the rHVT induced some protection against
irulent IBDV (60%) and low protection against MDV (10%
rotection) (Darteil et al., 1995). Therefore, further studies
re required to develop a more efficacious herpesvirus-
ased recombinant IBD vaccine that causes persistent
nfection in chickens.
In this study, we demonstrated that an effective and
afe herpesvirus-based IBD vaccine could be con-
tructed by expressing IBDV VP2 antigen at the US2 site
f serotype 1 MDV vaccine: effective protection against
ery virulent IBDV (vvIBDV) and full protection against
vMDV were achieved. Persistent infection of the rMDV
n chickens or continuous stimulation of the host immune
ystems by the VP2 antigen was suggested, because
ntibody levels against IBDV and MDV following the
accination increased continuously for at least 10 weeks.
ariation in the immune responses to VP2 was found.
RESULTS
nalysis of rMDV
Polymerase chain reaction (PCR) analysis of DNA pre-
ared from chicken embryo fibroblasts (CEFs) infected
ith the rMDV with primer pair P-MD1 and P-MD2 indi-
ated that the rMDV was isolated without contamination
f its parental CVI-988 (Figs. 1B and 1C). The findings
hat the PCR product prepared from the rMDV was hy-
ridized with both IBDV VP2 and MDV US2 probes indi-
ate that the VP2 expression cassette was inserted into
he expected US2 site of the CVI-988 genome by homol-
gous recombination (Figs. 1C and 1D).
Expression of IBDV VP2 protein in the rMDV was
learly demonstrated by the immunostaining of the
laques with anti-IBDV rabbit antibodies (Fig. 2A). West-
rn blot analysis of the cell lysate from the rMDV-infected lEFs with anti-IBDV rabbit antibodies indicated that the
olecular mass of the expressed VP2 was approxi-
ately 42 kDa (Fig. 2B). Several IBDV protein bands were
etected in the IBDV J1 strain-infected CEF lysates,
hereas there were no clear bands in the CVI-988-
nfected CEF lysates.
To determine the cellular localization of the expressed
P2, the rMDV-infected CEFs were incubated with anti-
BDV rabbit serum followed by horseradish peroxidase
HRPO)-conjugated goat anti-rabbit IgG before or after
he CEF cells were fixed with cold acetone. As a result,
he rMDV plaques were barely stained before the cell
ixation but were clearly stained after the fixation (Fig.
A). In addition, larger amounts of VP2 antigens were
etected in cell extracts from the rMDV-infected CEFs
han in the culture fluid using IBDV antigen-capture en-
yme-linked immunosorbent assay (ELISA) (Tsukamoto
t al., 1995a) (Fig. 3). These results indicate that the
xpressed VP2 was not present on the cell surface but
ccumulated in the cells.
rotection against vvIBDV
For determination of efficacy of the rMDV against
vIBDV, twenty 1-day-old SPF chicks were vaccinated
ith the rMDV and challenged 6 weeks later with 105
ID50 of vvIBDV Ehime/91 strain. All of the chickens
accinated with the rMDV or live IBDV vaccine, IBDV-A,
ere free of clinical signs and mortality after the chal-
enge (Table 1). Of the chickens vaccinated with rMDV or
BDV-A, 65 or 40%, respectively, had gross lesions after
he challenge. The gross lesions of the chickens vacci-
ated with the commercial vaccine IBDV-A might be
aused by the vaccine itself. In contrast, all of the chick-
ns vaccinated with CVI-988 and those in the challenge
ontrol group showed severe clinical signs and high
ortality (70–75%).
Histopathological examinations of BFs showed that
here were some variations in the BF lesion scores in
hickens vaccinated with rMDV after the challenge; some
hickens did not have any lesions (score 0, 4/20), whereas
ther chickens had mild (scores 1–4, 7/20) or severe (score
, 9/20) BF lesions (Table 2). The rMDV conferred 55%
rotection against vvIBDV in chickens (11/20) when no or
ild BF lesions (scores 0–4) were considered protected. In
ontrast, the IBDV-A vaccine conferred full protection
gainst vvIBDV; all of the chickens had BF lesion scores of
ess than 4 (20/20). Both the challenge control chickens and
he chickens vaccinated with CVI-988 had severe BF le-
ions (score 5, 20/20) (Table 1).
The association between enzyme immunoassay (EIA)
ntibody titers to IBDV before the challenge and the BF
esion scores in the rMDV-vaccinated chickens was de-
ermined. There was a tendency for chickens with the
ow antibody titers (20 or 40) to IBDV to have a severe BF
esion score (score 5). Although all of the chickens pro-
d
v
v
c
2
c
l
C
v
V
a
P
a
e
e
m
w
9
h
r
v
u
t
l
A
r
r
a
r
a
c
f
a
i
l
A
C
g
w
S
354 TSUKAMOTO ET AL.uced the anti-IBDV antibodies 6 weeks after the rMDV
accination, the anti-IBDV antibody titers of the rMDV-
accinated chickens were much lower than those of the
hickens vaccinated with the live IBDV-A vaccine (Table
). The geometric mean antibody titer of the rMDV-vac-
inated chickens was approximately 1/30 of that of the
ive IBDV-A vaccinated chickens when IBDV-infected
EF cells were used as the antigen. In four chickens
accinated with the rMDV, a low antibody level against
P2 (titer 40 or 80) was sufficient to protect the chickens
gainst vvIBDV challenge.
rotection against vvMDV
To determine the efficacy of the rMDV vaccine
gainst vvMDV, the RB1B strain, the vaccinated chick-
ns were challenged 7 days after the vaccination and
xamined for clinical MD signs and tumor develop-
ents for another 6 weeks. The chickens vaccinated
ith the rMDV, as well as those vaccinated with CVI-
FIG. 1. (A) Gene structure of the rMDV. Both MDV US2 and IBDV
mplification of MDV US2 gene by PCR. The US2 gene was amplified f
VI-988-infected CEF cells. The reaction products were submitted to a
ene was amplified from DNAs prepared from CVI-988-infected CEF ce
ith the MDV US2 probe. p2EG directly underwent Southern blot an
outhern blot analysis with the IBDV VP2 probe.88, did not show any clinical signs and had no gross/istopathological tumors (Table 3), indicating that the
MDV could confer full protection to chickens against
vMDV. Ninety percent (18/20) of the chickens in the
nvaccinated challenge control group died of MD, and
he remaining 2 chickens had histopathological MD
esions at the necropsy.
ntibody responses and contact transmission
Antibody responses of chickens vaccinated with the
MDV were tested for 10 weeks by the EIA tests. As a
esult, some variations in anti-IBDV antibody titers
mong the chickens vaccinated with the rMDV were also
evealed; most of the chickens (8/9) produced anti-IBDV
ntibodies up to 6 weeks after the vaccination, but one
hicken did not produce the antibodies up to 10 weeks
ollowing the vaccination (Table 4). It was shown that the
ntibody titers to IBDV increased gradually in the remain-
ng 8 chickens after the vaccination with rMDV, for at
east 10 weeks.
obes and the primer pairs to synthesize the probes are shown. (B)
As prepared from the p2EG plasmid, the rMDV-infected CEF cells, or
gel electrophoresis and stained with ethidium bromide. (C) The US2
he rMDV-infected CEF cells, and processed for Southern blot analysis
without PCR amplification. (D) The same DNAs were processed forVP2 pr
rom DN
garose
lls, or t
alysisAntibody titers against MDV were also measured by
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355PROTECTION AGAINST IBDV AND MDV WITH RECOMBINANT MDVhe EIA tests to investigate the persistent infection by the
MDV in chickens. The data summarized in Table 4
learly indicate that the anti-MDV antibody titers gradu-
lly increased and reached a level similar to those of
hickens vaccinated with CVI-988. These serological
ata suggest persistent infection by the rMDV in chick-
ns or continuous stimulation of the immune systems by
he VP2 antigen.
No evidence of contact transmission of the rMDV
rom nine rMDV-vaccinated chickens to their two SPF
enmates was detected during the experimental pe-
iod by the serological tests (Table 4). This was con-
irmed by histopathological examinations of the pen-
ates; no histopathological changes were detected.
wo SPF penmates reared with chickens vaccinated
ith CVI-988 produced anti-MDV antibodies from 8
eeks of age, and the histopathological changes in
nfection were detected at necropsy (Table 4). These
esults indicate that contact transmission of the rMDV
as not detected in this experiment, although horizon-
al transmission of the parent virus was observed. It is
ossible that contact transmission of the rMDV may
ccur but at a level below that detectable in this assay
two birds), and it seems reasonable that contact
ransmission of the rMDV does not exceed that of its
FIG. 2. (A) Immunological staining of the CVI-988 or rMDV plaque
DV-infected cells. The plaques on the left were not fixed with acetone (
oat anti-rabbit IgG antibodies, and a DAB substrate. The plaques on
repared from the rMDV-infected CEF cells were subjected to SDS–poly
he blotted membrane was blocked and reacted with rabbit anti-IBDV
CL Western blotting detection reagents.s with rabbit anti-IBDV antibodies with or without acetone fixation of the
Acetone (2)) but were incubated with anti-IBDV antibodies, HRPO-conjugated
the right were stained after acetone fixation (Acetone (1)). (B) CEF lysates
acrylamide gel electrophoresis and transferred to a nitrocellulose membrane.
antibodies followed by HRPO-conjugated goat anti-rabbit IgG antibodies andarent virus CVI-988. cFIG. 3. Detection of the IBDV VP2 antigen produced in the culture
luids and cell lysates from the rMDV-infected CEF cells. These sam-
les prepared from the CVI-988-infected CEF cells were used as a
ontrol. The VP2 antigens were detected by antigen-capture ELISA.
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356 TSUKAMOTO ET AL.accine safety
Histopathological examinations of the rMDV-vacci-
ated chickens were done 10 weeks after the vaccina-
ion to determine the safety of the rMDV vaccine in
hickens. No lesions were found in any of the tissues
ested from the rMDV-vaccinated chickens as well as
rom those vaccinated with the parent virus CVI-988.
hese data clearly demonstrate the safety of the rMDV
or chickens.
DISCUSSION
rHVT/rMDV vaccines have been developed for New-
astle disease virus (NDV), an avian paramyxovirus,
hich causes a highly contagious and fatal respiratory
isease in birds (Heckert et al., 1996; Morgan et al., 1992;
eddy et al., 1996; Sakaguchi et al., 1998). The rHVT
xpressing NDV fusion (F) envelope glycoprotein at the
S10 site offered 90% protection against an intramuscu-
ar challenge with velogenic NDV (Morgan et al., 1992).
ore recently, rHVT expressing both hemagglutinin–
euraminidase (HN) and F envelope glycoproteins pro-
ected all of the chickens tested against velogenic NDV
T
Efficacy of the rMDV, IBDV-A, and CVI-988 Vacc
accine Challenged with Clinical signs Mortality
MDV Ehime/91 2 0% (0/20)
BDV-A Ehime/91 2 0% (0/20)
VI-988 Ehime/91 1 70% (14/20
— Ehime/91 1 75% (15/20
— — 2 0% (0/10)
Note. One-day-old SPF chickens were vaccinated with the rMDV or
BDV-A (live IBDV vaccine) was inoculated into 20-day-old SPF chicken
a Number of chickens with no or mild BF lesion scores (0 to 4)/num
T
Relationship between Serum Antibody Titers to IBDV an
with the rMDV and Challen
accine Ab titers to IBDV Gross BF lesions
rMDV 20a 6/6
40 4/10
80 2/3
160 1/1
Average 37 Total 13/20
IBDV-A Average 1151 8/20
Note. One-day-old SPF chickens were vaccinated with the rMDV and
BDV-A vaccine and challenged at 6 weeks of age. The Ehime/91 straa Sera were collected before the challenge, and the antibody titers againstHeckert et al., 1996; Reddy et al., 1996). It was shown
hat both rHVT and rMDV expressing NDV were applica-
le to field chickens with maternal antibodies (Morgan et
l., 1993; Sakaguchi et al., 1998). However, only one
aper reported construction of rHVT expressing IBDV
P2, which conferred partial protection against IBDV
60%) and poor protection against vvMDV (10%), and the
n vivo replication was inefficient (Darteil et al., 1995).
In this study, we constructed an rMDV expressing the
BDV VP2 antigen, which conferred partial protection
gainst vvIBDV (55%) and full protection against vvMDV
Tables 1, 2, and 3). The criteria that the no/mild BF
esions are considered protected means that the rMDV
uppressed the damage caused by vvIBDV to a level
qual to or milder than those caused by IBDV vaccine
trains. Both the rMDV and the rHVT expressing VP2
howed partial protection against IBDV; however, the
MDV may be more efficacious because the rMDV was
valuated at a higher dose (105.0 EID50/chicken) of very
irulent IBDV (70% mortality to SPF chickens), whereas
he rHVT was evaluated at a lower dose (102.5 EID50/
hicken) of virulent IBDV (vIBDV) (mild clinical signs). The
MDV conferred full protection against vvMDV (Table 3),
ainst vvIBDV Ehime/91 Strain in SPF Chickens
Gross BF lesions
Average histopathology
BF lesion scores Protection
65% (13/20) 3.3 55% (11/20)a
40% (8/20) 1.6 100% (20/20)
100% (20/20) 5.0 0% (0/20)
100% (20/20) 5.0
0% (0/10) 0.0
8 strains and challenged with vvIBDV Ehime/91 strain 6 weeks later.
ch were challenged at 6 weeks of age as above.
ted.
pathological BF Lesion Scores in Chickens Vaccinated
th vvIBDV Ehime/91 Strain
Histopathological BF lesion scores
1 2 3 4 5 Average
1 5 4.8
2 1 4 2.5
1 1 2.3
1 4.0
2 2 3 9 3.3
13 1 4 1.6
ged 6 weeks later. Twenty-day-old SPF chickens were vaccinated with
IBDV was used as a challenge strain.ABLE 1
ines ag
)
)
CVI-98
s, whiABLE 2
d Histo
ged wi
0
3
1
4
2
challen
in of vvIBDV were measured by indirect EIA tests.
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357PROTECTION AGAINST IBDV AND MDV WITH RECOMBINANT MDVhereas the rHVT offered poor protection (10% protec-
ion). Serological data suggest that the rMDV should
nfect chickens persistently or stimulate host-immune
ystems continuously (Table 4). In contrast, in vivo rep-
ication of the rHVT was poor or absent (Darteil et al.,
995). It was shown that the gI site, which was used to
xpress the VP2 in the rHVT, plays an important role in
ell-to-cell transmission of HSV-1 in vivo (Balan et al.,
994). Recombinant fowlpox virus (rFPV)-based IBD vac-
ines have also been reported; however, their efficacy
as not satisfactory (Bayliss et al., 1991; Heine and
oyle, 1993). Chickens vaccinated with rFPV at 1 and 14
ays of age were not protected against the gross BF
esions after challenge with vvIBDV (Bayliss et al., 1991).
o lesions in chickens vaccinated with the rMDV and no
ontact transmission of the rMDV to SPF penmates were
onfirmed (Table 4). These results indicate that a more
fficacious and safer herpesvirus-based IBD vaccine
as constructed by expressing the VP2 gene at the US2
ite of serotype 1 MDV, CVI-988. Nevertheless, the effi-
acy is lower than that of conventional IBDV live vac-
ines (Tables 1 and 2) (Ismail and Saif, 1991; Tsukamoto
t al., 1995b). Further studies are required to improve the
fficacy of the rMDV.
T
Efficacy of the rMDV and CVI-988 Vaccine
accines Challenged with Clinical signs Mort
rMDV RB1B 2 0% (0
CVI-988 RB1B 2 0% (0
— RB1B 1 90% (1
— — 2 0% (0
Note. One-day-old SPF chickens were vaccinated with the rMDV or C
igns and mortality were then observed for 6 weeks, and both dead c
istopathological examinations. Chickens with gross tumor lesions we
T
Geometric Mean Serum Antibody Titers
with the rMDV or CVI-988 Vaccines
accine Antibodies to No. of chickens 2
rMDV IBDV 9 0 (0/9
2 penmates 0
MDV 9 7 (4
2 penmates 0
CVI-988 IBDV 7 0
2 penmates 0
MDV 7 24 (7
2 penmates 0
Note. One-day-old SPF chickens were vaccinated with the rMDV or C
n isolater. Sera were collected at 2-week intervals.a Serum antibody titers were measured by indirect EIA tests. No. positive/nThere are several factors affecting efficacy of the re-
ombinant herpesvirus vaccines: vector virus strains,
nsertion sites in the vector virus genome, promoters,
nd host-protective antigens. We used the CVI-988 vac-
ine strain as a vector, US2 as a gene insertion site, and
n SV40 early promoter to construct the rMDV, whereas
arteil et al. (1995) used an HVT as a vector, the gI
UL40) as a gene insertion site, and a CMV promoter.
here are several reasons for our construction. (i) The
VI-988 is the most effective MD vaccine obtained thus
ar and may replicate efficiently in chickens (Witter et al.,
995). (ii) It was shown that insertion of a marker gene at
he US2 site did not affect the viral replication of the
ecombinant virus in chickens (Cantello et al., 1991; Par-
ells et al., 1994). Antibody responses against IBDV and
DV following the vaccination increased gradually until
he end of this experiment (10 weeks) (Table 4), and the
ntibody titers to MDV of chickens vaccinated with the
MDV were comparable to those of chickens vaccinated
ith the parental CVI-988 (Table 4). These data suggest
hat the rMDV may persistently infect chickens as effi-
iently as the parent virus CVI-988. From these view-
oints, our strategy may be useful for constructing effi-
acious rMDV vaccines for other infectious diseases.
nst vvMDV RB1B Strain in SPF Chickens
Gross MD lesions
Histopathological
MD lesions Protection
0% (0/18) 0% (0/18) 100%
0% (0/20) 0% (0/20) 100%
95% (19/20) 100% (20/20)
0% (0/10) 0% (0/10)
vaccines and challenged 7 days later with vvMDV RB1B strain. Clinical
and the surviving chickens necropsied were subjected to gross and
sidered positive for histopathological lesions.
IBDV and MDV of Chickens Vaccinated
ose of Each of Two SPF Penmates
Weeks after vaccination
4 6 8 10
5 (5/9) 17 (8/9) 31 (8/9) 45 (8/9)
0 0 0 0
200 (9/9) 341 (9/9) 584 (9/9) 858 (9/9)
0 0 0 0
0 0 0 0
0 0 0 0
316 (7/7) 631 (7/7) 848 (7/7) 848 (7/7)
0 0 79 (2/2) 224 (2/2)
vaccines and reared for 10 weeks with each of two SPF penmates inABLE 3
s agai
ality
/18)
/20)
8/20)
/10)
VI-988
hickensABLE 4
against
and Th
)a
/9)
/7)
VI-988umber tested.
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358 TSUKAMOTO ET AL.It is known that the VP2 is a conformational antigen
Becht et al., 1988; Fahey et al., 1989). Denatured VP2
oes not induce protection in chickens (Fahey et al.,
989), and denatured and renatured VP2 also lost the
bility to induce neutralizing antibodies in chickens (O¨p-
ling et al., 1991b). Multimeric forms of VP2 were highly
mmunogenic, whereas the monomeric forms were non-
mmunogenic (Azad et al., 1991). Therefore, the rMDV
hould express structurally native VP2 as well as other
ector systems such as yeast (Fahey et al., 1991a; Ma-
readie et al., 1990), baculovirus (Snyder et al., 1994;
akharia et al., 1993, 1994), FPV (Bayliss et al., 1991;
eine and Boyle, 1993; Heine et al., 1994), and HVT
Darteil et al., 1995). The VP2 expressed by rMDV was
ardly detected on the cell surface unless the rMDV-
nfected CEF cells were fixed with acetone (Fig. 2A),
ndicating that the expressed VP2 was not present on the
ell surface but accumulated in the cells. Intracellular
ocalization of VP2 corresponds to the previous study, in
hich VP2 expressed by rFPV was nonglycosylated and
bsent on the cell surface (Heine and Boyle, 1993). It was
hown that modifications of VP2 to cell surface localiza-
ion by adding a transmembrane domain or a secreted
orm of VP2 by adding secretion signal peptides failed to
nhance immunogenicity (Heine et al., 1994). These data
lso suggest that intracellular localization of VP2 may be
ritical to preserve the native conformational structure of
P2.
Serological tests are a good indicator to determine the
fficacy of the rMDV, because serum neutralizing anti-
odies to VP2 play an important role in IBDV protection
Fahey et al., 1991b; Lukert and Saif, 1997). There was a
endency for the chickens with lower anti-IBDV antibody
iters before the challenge (EIA antibody titer of 20 or 40)
o have severe BF lesions (score 5), whereas chickens
ith higher antibody titers (40–160) had no or mild BF
esions (score 0–4) (Table 2). We confirmed that the
ntiserum had virus-neutralizing activity against IBDV
data not shown). However, unexpectedly, a small
mount of antibodies against VP2 was sufficient to pro-
ect chickens against clinical IBD (Table 2). In particular,
espite the low level of the antibodies, four chickens
ere protected completely (no BF lesions). Higher virus-
eutralizing antibody titers (approximately 103) are usu-
lly required to protect chickens against IBDV when
urified VP2 is injected into the chickens (Macreadie et
l., 1990; Vakharia et al., 1993, 1994). These data suggest
hat the rMDV might induce cellular immunity to VP2,
hich might work effectively for IBDV protection. Al-
hough cellular immunity to IBDV has not been demon-
trated, it is speculated that rFPV-based IBD vaccines
ight protect chickens via the stimulation of cell-medi-
ted immunity (Bayliss et al., 1991). Further studies are
equired to determine which is more effective in protect-
ng chickens against IBDV infection, humoral immunity or
ell-mediated immunity. cAlthough live IBDV vaccines proved highly immuno-
enic and effective in chickens (Ismail and Saif, 1991;
sukamoto et al., 1995b), there are several advantages to
he rMDV vaccine developed here. (i) This rMDV is a
ubunit vaccine. Therefore, it does not induce side ef-
ects in the BF, and the intact BF may work effectively for
ther disease vaccinations. In contrast, live IBDV vac-
ines induce atrophy of the BF (Mazariegos et al., 1990;
sukamoto et al., 1995b). (ii) Variant IBDV strains do not
ome from the rMDV, whereas live IBDV vaccines may
roduce pathogenically or antigenically variant strains
Muskett et al., 1985). Antigenic variant IBDV strains,
hich are difficult to control by classical types of live
BDV vaccines (Jackwood and Saif, 1987; Sharma et al.,
989), are suspected to be derived from live IBDV vac-
ines (Giambrone and Closser, 1990). It may be possible
hat both classical and variant types of IBDV could be
ontrolled by an rMDV expressing both classic and vari-
nt types of VP2 antigens. (iii) It is expected that the
rotective immunity to IBDV will continue for an extended
eriod of time, because the vaccine is a herpesvirus. (iv)
t was shown in this study that contact transmission of
he rMDV to the SPF penmates did not occur (Table 4),
hereas live IBDV vaccines are transmitted from chicken
o chicken (Tsukamoto et al., 1995b).
MATERIALS AND METHODS
Viruses, cell culture, and chickens. The CVI-988 vac-
ine strain of serotype 1 MDV was used as a parent virus
or construction of an rMDV. MDVs were propagated in
EFs prepared from 10-day-old embryonated eggs ob-
ained from our SPF chicken flock, line PDL-1 (Furuta et
l., 1980), using growth medium consisting of Dulbecco’s
EM (Nissui, Tokyo, Japan), 5% fetal calf serum, 10%
ryptose phosphate broth, and antibiotics. The Ehime/91
train of vvIBDV (Tsukamoto et al., 1992) was used to
lone the host-protective antigen gene of the VP2. The
hime/91 and vvMDV RB1B strains (Schat et al., 1982)
ere used as challenge viruses.
All white leghorn SPF chickens were purchased from
PAFAS (Norwich, CT) and reared in negative-pressure
solators set in a negative-pressure chicken house.
Detection of antibodies to IBDV and MDV. Antibodies
gainst IBDV VP2 and MDV were detected by an EIA.
EF-adapted IBDV J1CEF72 strain (3 3 106 PFU) (Tsuka-
oto et al., 1995a) was inoculated into 10 ml of primary
EF cells (8 3 106 cells) in a 96-well plate (Falcon,
incoln Park, NJ) and the cells were cultured for 24 h.
fter removal of the medium and subsequent rinsing of
he cells twice with phosphate-buffered saline (PBS), the
ells were fixed with a fixation solution (70% acetone in
ater) for 5 min at room temperature. After removal of the
ixation solution, the antigen-coated plates were stored
t 280°C before use. For preparation of MDV-infected
ells, 3% of the CVI-988-infected CEFs were cocultivated
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359PROTECTION AGAINST IBDV AND MDV WITH RECOMBINANT MDVith primary CEF cells (3 3 104 cells) for 4 days in
6-well plates, fixed, and stored as described above.
erum samples were diluted with a diluent (5% skim milk
owder/PBS), and the diluted samples were added to
ells coated with IBDV- or MDV-infected cells. After
ncubation for 1 h at 37°C and a subsequent washing of
he cells, the plates were incubated with HRPO-conju-
ated goat anti-chicken IgG (Fc) (1:500 dilution with the
iluent; Bethyl Laboratories, Inc., Montgomery, TX). After
ncubation at 37°C for 30 min and washing, the substrate
3,39-diaminobenzidine tetrahydrochloride) was added
or color development. After incubation for 10 min, the
nzyme reaction was stopped by replacing the substrate
olution with water, and the cells were observed under a
ight microscope.
Western blotting analysis. Lysates of CEFs infected
ith rMDV, CVI-988, or IBDV J1CEF72 strains were sub-
ected to a sodium dodecyl sulfate (SDS)–12.5% poly-
crylamide gel electrophoresis (PAGE) followed by a
estern blotting analysis. CEF cells infected with IBDV
1CEF72 strain were harvested 20 h after the virus inocu-
ation, and the cell lysate was used as the positive
ontrol. Anti-IBDV rabbit antiserum (Tsukamoto et al.,
995a) and enhanced chemiluminescence (ECL) West-
rn blotting detection reagents (Amersham, Bucking-
amshire, England) were used.
Detection of IBDV VP2 antigens by ELISA. The IBDV
P2 antigens produced from the rMDV were measured
y an antigen-capture ELISA as described previously
Tsukamoto et al., 1995a). A CEF monolayer in a 6-well
issue culture plate was inoculated with 1000 PFU of the
MDV and cultured for 5 days. The CVI-988 was used as
control. The cytopathic effects were observed, and
hen both the culture supernatant and the cells were
arvested from 1 well per day and stored at 280°C. The
upernatants were mixed with an equal amount of ELISA
iluent, and the cell lysates were homogenized in an
qual volume of the same ELISA diluent. These samples
ere subjected to the measurement of the VP2 antigen
y ELISA.
Generation of expression cassette. Total MDV DNA
as prepared from the CVI-988-infected CEFs as de-
cribed previously (Morgan et al., 1990) and used as a
emplate to amplify a 6.5-kb MDV DNA fragment covering
he US2 region with two primers, P-MD9 (59-ACCATG-
AAACCCGATGTCG-39) and P-MD10 (59-ATGCCCGTCT-
GATGGACGA-39). These primers were made according
o the US region sequences of MDV GA strain
Brunovskis and Velicer, 1995). The 6.5-kb fragment was
loned into a plasmid vector, pCRII (Invitrogen Corp., San
iego, CA), according to the manufacturer’s recommen-
ations. Part of the US2 region was sequenced with two
rimers, P-MD1 (59-GGTTGTAGCGATGCACCTAAT-39)
nd P-MD2 (59-TAGTTTTAACCCTGTTTCATA-39). The con-
truct was digested with SalI–BamHI and the SalI–
amHI fragment (6.5 kb) was recloned into a vector nUC18, and the plasmid was designated pUS2 (Sam-
rook et al., 1989). The entire putative VP2 gene (from
ucleotides 1 to 1359 of segment A open reading frame)
as amplified from viral RNA prepared from the Ehime/
1-infected bursal homogenates by using an RNA PCR
it (Takara Shuzo Co., Shiga, Japan) and two primers,
-IBD1 (59-ATAAGAATGCGGCCGCATGACAAACCTGCA-
GATCAAACCCA-39) and P-IBD2 (59-ATAGTTTAGCGGC-
GCTTACCTCCTTATAGCCCGGATTATGT-39) (Brown et
l., 1994; Brown and Skinner, 1996). The VP2 gene was
loned into a plasmid vector, pSVb (Clontech Laborato-
ies, Palo Alto, CA), by replacing the b-galactosidase
ene, and plasmid pSV-VP2 was obtained. The pSV-VP2
lasmid was digested with EcoRI/HindIII, and the result-
ng 2.0-kb DNA fragment that contained SV40 early pro-
oter, the putative entire VP2 gene, and the SV40 poly-
denylation signal was cloned into the BglII site in the
S2 region of the transfer vector pUS2 after the ends
ere blunted. The expression cassette was designated
2EG.
Construction of rMDV. Transfection of the expression
assette p2EG into CEFs was done as described previ-
usly (Sakaguchi et al., 1993). Briefly, CEFs (8 3 106 cells)
ere cultivated with the CVI-988-infected CEFs (5 3 105
ells) for 4 h, and then the cells were trypsinized. The cell
uspensions were mixed with 40 mg of p2EG in 0.7 ml of
BS and electroporated in an electric field (1.5 kV/cm) at
oom temperature for 0.5 ms using gene pulser (Bio-Rad
aboratories, Hercules, CA). After 3 days of cultivation in
tissue culture dish, the cells were transferred into
6-well tissue culture plates and cultured until the
laques were visible. Duplicates of the culture were
ade, and one of the plates was stained with anti-IBDV
abbit IgG followed by HRPO-conjugated anti-rabbit IgG
goat IgG) by the EIA. Antigen-positive wells of the other
late were subcultured. The cloning process was re-
eated until most of the plaques became immunologi-
ally positive. Then the infected cells were sonicated and
he resulting supernatant was inoculated onto CEFs to
btain pure rMDV.
PCR and Southern blot analysis. To determine whether
he rMDV was contaminated with wild-type CVI-988, a
CR amplification that covered the US2 region with two
rimers, P-MD1 (59-GGTTGTAGCGATGCACCTAAT-39) and
-MD2 (59-TAGTTTTAACCCTGTTTCATA-39), was performed
gainst high-molecular-weight DNA prepared from MDV-
nfected CEFs. The amplified PCR products were hybrid-
zed with MDV US2 or IBDV VP2 probes. The US2 and
P2 probes were labeled with digoxigenin (DIG) accord-
ng to the manufacturer’s manual (Boehringer Mannheim,
annheim, Germany) using primer pairs P-MD1/P-MD2
nd P-IBD5 (59-CCATAAACGCCGTGACCTTC-39)/P-IBD10
59-ATCCTGTTGCCACTCTTTCG-39) (Brown et al., 1994;
rown and Skinner, 1996), respectively. The DIG-labeled
ybridized DNA was detected by enzyme-linked immu-
oassay using anti-DIG antibodies conjugated with alka-
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360 TSUKAMOTO ET AL.ine phosphatase and subsequent enzyme-catalyzed
olor reaction with 5-bromo-4-chloro-3-indolyl phosphate
nd nitro blue tetrazolium salt.
Protection against vvIBDV. A total of 90 SPF chickens
ere used in this experiment. Each of twenty 1-day-old
PF chickens was vaccinated with the rMDV (104 PFU/
hick) or the CVI-988 (5 3 103 PFU/chick) subcutane-
usly (sc). Twenty 20-day-old SPF chickens were inocu-
ated orally with 1 dose of a conventional live IBDV
accine, IBDV-A. All of the chickens were bled at 6 weeks
f age, and the sera were tested for antibody titers
gainst IBDV J1 strain (Tsukamoto et al., 1995a) by the
IA. The chickens were then challenged orally with the
vIBDV Ehime/91 strain (105 50% of egg infective dose
EID50)/chick). Twenty unvaccinated challenged SPF
hickens and 10 unvaccinated unchallenged SPF chick-
ns were used as challenge and negative controls, re-
pectively. The chickens were examined for clinical
igns and mortality for 7 days, and both dead chickens
nd surviving chickens that were sacrificed were sub-
ected to gross and histopathological examinations for
F lesions. BFs were fixed in 10% buffered formalin
olution and subjected to the conventional paraffin-em-
edding procedure for hematoxylin and eosin staining.
he histopathological BF lesions were classified into five
ategories (1–5) as described previously (Tanimura et al.,
995). The extent of histologic lesions was scored on the
asis of lymphoid necrosis and/or depletion: a score of
5 ,5% affected follicles; a score of 1 5 5–25% affected
ollicles; a score of 2 5 25–50% affected follicles; a score
f 3 5 50–75% affected follicles; a score of 4 5 .75%
ffected follicles; and a score of 5 5 nearly 100% affected
ollicles with acute inflammatory infiltration. The scores
f 1–4 are a consequence of the infection with attenu-
ted live IBDV vaccines, whereas a score of 5 is the
esult of the virulent or very virulent IBDV infection
Tsukamoto et al., 1995b). Thus, our criterion for protec-
ion is a score of 0–4 after the challenge.
Protection against vvMDV. A total of 68 SPF chickens
ere used in this experiment. Each of twenty 1-day-old
PF chickens was vaccinated with the rMDV or the
VI-988 as above and challenged 7 days later with the
vMDV RB1B strain (500 PFU/chick) intraperitoneally.
wenty unvaccinated challenged SPF chickens and 10
nvaccinated unchallenged SPF chickens were used as
hallenge and negative controls, respectively. The chick-
ns were examined for clinical signs and mortality for 6
eeks after the challenge. Both dead chickens and sur-
iving chickens that were sacrificed were subjected to
ross and histopathological observations for MD lesions
n the liver, kidneys, spleen, nerves, and skin.
Monitoring of antibody responses, safety, and contact
ransmission to chickens. A total of 20 SPF chickens
ere used for determination of the antibody responses
o the rMDV as well as the safety of the rMDV for
hickens. Nine 1-day-old SPF chickens were inoculated Cith rMDV. Seven 1-day-old SPF chickens were inoc-
lated with CVI-988 and used as the control. The
era were collected at 2-week intervals until the chick-
ns reached 10 weeks of age. The serum antibody
iters against IBDV and MDV were measured by the
IA. Ten weeks after the vaccination, these chickens
ere necropsied for histopathological examination in
ajor tissues (cerebrum, optic lobe, cerebellum, brain
tem, lumbosacral enlargement, siatic nerve, skin, skel-
tal muscle, BF, thymus, spleen, cecal tonsil, proventric-
lus, duodenum, pancreas, heart, lungs, liver, kidney, and
vary/testis).
In addition, for determination of the contact transmis-
ion of the rMDV, two SPF chickens were reared for 10
eeks in the same isolator with the nine chickens vac-
inated with the rMDV. As a control, two SPF chickens
ere also reared with the seven chickens vaccinated
ith the CVI-988. Sera were collected at 2-week intervals
rom their penmates and measured for the presence of
ntibodies against IBDV and MDV by the EIA tests. Then
he penmates were also necropsied and the tissues
liver, kidney, spleen, nerve, and skin) were subjected to
he histopathological examinations to determine the con-
act transmission of the rMDV.
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